FDA flexibility described as 'evolving'

Food and Drug Administration flexibility is still showing up in biotech meetings, but companies say it depends on the program and the review team. BioSpace reported April 13 that executives at Rezolute and CERo Therapeutics described recent discussions with reviewers as collaborative rather than rigid. (biospace.com) Rezolute pointed to a September 2, 2025 agreement on its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism, a disorder that drives dangerous low blood sugar. The company said the Food and Drug Administration let it drop a double-blind, placebo-controlled portion and run a single-arm, open-label study in as few as 16 patients. (rezolutebio.com) Rezolute also said the agency agreed its separate sunRIZE trial in congenital hyperinsulinism could serve as confirmatory clinical evidence for the tumor setting. The company said that pivotal congenital hyperinsulinism study was on track to report topline results in December 2025, with tumor-hyperinsulinism data expected in the second half of 2026. (rezolutebio.com) CERo Therapeutics described a similar tone on its cell therapy program, CER-1236, in acute myeloid leukemia, a fast-moving blood cancer. The company dosed its first Phase 1 patient on May 30, 2025, after the Food and Drug Administration cleared a chemistry, manufacturing and controls amendment in March 2025. (markets.financialcontent.com) (curetoday.com) By January 2026, CERo said it had filed a Food and Drug Administration amendment to add advanced myelodysplastic syndrome and myelofibrosis cohorts to that study. BioSpace said the company had also cited an unexpectedly positive response in a patient whose acute myeloid leukemia had progressed to myelodysplastic syndrome. (marketscreener.com) (biospace.com) The backdrop is a year of mixed signals from the agency, especially in rare disease drug development. BioSpace reported on April 6 that some developers saw reversals on whether external controls — comparisons built from natural history or real-world data instead of a randomized control arm — could support approval packages. (biospace.com) At the same time, the Food and Drug Administration has been formalizing a more permissive message in cell and gene therapy. On January 11, 2026, the agency said it was publicizing a flexible approach to chemistry, manufacturing and control requirements for those products after years of applying some flexibilities case by case. (fda.gov) That message has also shown up in guidance. The Food and Drug Administration’s cell and gene therapy guidance page lists September 2025 draft documents on expedited programs for regenerative medicine therapies, innovative trial designs in small populations and postapproval data collection methods. (fda.gov) The thread running through all of it is narrower than the rhetoric. Companies are still finding room to negotiate smaller studies, single-arm designs and manufacturing changes, but BioSpace’s reporting shows those openings are arriving unevenly, one program at a time. (biospace.com)